Literature DB >> 27070940

Adverse event reporting in oncology clinical trials - lost in translation?

Shanthi Sivendran1, Matthew D Galsky2.   

Abstract

Keywords:  Adverse event; CONSORT; attribution; harms; patient reported outcomes

Mesh：

Substances：

Year:  2016        PMID： 27070940     DOI： 10.1080/14740338.2016.1175429

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN： 1474-0338            Impact factor:   4.250


× No keyword cloud information.
  7 in total

Review 1.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2018-06-18       Impact factor: 18.959

2.  NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.

Authors:  Jeffrey J Kirshner; Maxwell C McDonald; Flavio Kruter; Andrew S Guinigundo; Linda Vanni; Cathy L Maxwell; Maureen Reiner; Terry E Upchurch; Jacob Garcia; Phuong Khanh Morrow
Journal:  Support Care Cancer       Date:  2017-11-16       Impact factor: 3.603

3.  Identification, collection, and reporting of harms among non-industry-sponsored randomized clinical trials of pharmacologic interventions in the critically ill population: a systematic review.

Authors:  Ari Moskowitz; Lars W Andersen; Mathias J Holmberg; Anne V Grossestreuer; Katherine M Berg; Asger Granfeldt
Journal:  Crit Care       Date:  2020-07-08       Impact factor: 9.097

4.  EQUATOR-Oncology: reducing the latitude of cancer trial design and reporting.

Authors:  Habeeb Majeed; Eitan Amir
Journal:  Br J Cancer       Date:  2018-02-22       Impact factor: 7.640

Review 5.  Reporting guidelines for oncology research: helping to maximise the impact of your research.

Authors:  Angela MacCarthy; Shona Kirtley; Jennifer A de Beyer; Douglas G Altman; Iveta Simera
Journal:  Br J Cancer       Date:  2018-02-22       Impact factor: 7.640

6.  Serious adverse events of older adults in nursing home and community intervention trials.

Authors:  Rupak Datta; Mark Trentalange; Peter H Van Ness; Joanne M McGloin; Jack M Guralnik; Michael E Miller; Michael P Walkup; Neelesh Nadkarni; Marco Pahor; Thomas M Gill; Vincent Quagliarello; Manisha Juthani-Mehta
Journal:  Contemp Clin Trials Commun       Date:  2017-12-21

7.  Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis.

Authors:  Matías Rodrigo Chacón; Diego Hernán Enrico; Jeannette Burton; Federico Daniel Waisberg; Viviana Marina Videla
Journal:  JAMA Netw Open       Date:  2018-12-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.